Effect of Cannabinoid Receptor Agonists on Streptozotocin-Induced Hyperalgesia in Diabetic Neuropathy
Abstract
The effect of CB-1 and CB-2 receptor agonists, as well as an influence of a non-selective inhibitor of nitric oxide synthase (NOS), L-NOArg, and an inhibitor acting preferentially on cyclooxygenase-1 (COX-1), indomethacin, on the action of cannabinoid receptor agonists in a streptozotocin (STZ)-induced neuropathic model was investigated. When administered alone, a non-selective cannabinoid receptor agonist, WIN 55,212-2, a potentially selective CB-1 cannabinoid receptor agonist, Met-F-AEA, and a selective CB-2 cannabinoid receptor agonist, AM1241, dose-dependently reduced STZ-induced hyperalgesia. The results of the present study also demonstrated that inhibitors of COX and NOS increase antihyperalgesic activity of low doses of CB-1 and CB-2 receptor agonists. Hypothetical consequences of this phenomenon are discussed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Either single or repeated administration of WIN55,212-2 or AM1241 dose-dependently attenuated STZ-induced hyperalgesia.
“In particular, either single or repeated administration of WIN55,212-2 or AM1241, dosedependently attenuated STZ-induced hyperalgesia (Bujalska, 2008).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Bujalska, 2008
THC and WIN55,212-2 produce antinociception in rodent STZ-induced peripheral neuropathy.
“Several studies have demonstrated that THC (Williams et al, 2008) and WIN55,212-2 (Bujalska, 2008;Doğrul et al, 2004;Ikeda et al, 2013;Jahanabadi et al, 2016;Mohammadi-Farani et al, 2010;Ulugol et al, 2004;Vera et al, 2012;Vincenzi et al, 2013) produce antinociception in rodent STZinduced peripheral neuropathy.”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Bujalska, 2008
Daily pretreatment with indomethacin or L-NOArg increased the anti-hyperalgesic actions of low doses of WIN55,212-2, AM1241, and MET-F-AEA in streptozotocin rats to a greater extent than the cannabinoid alone.
“Daily pre-treatment with indomethacin (COX-1 inhibitor) or L-NOArg (non-selective NOS inhibitor) increased the anti-hyperalgesic actions of low doses of WIN55,212-2, AM1241 and MET-F-AEA in STZ rats to a greater extent than the cannabinoid administered alone, suggesting the presence of antinociceptive synergism between cannabinoid and COX pathways.107”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [107]
There is antinociceptive synergism between cannabinoid and COX pathways in streptozotocin rats.
“suggesting the presence of antinociceptive synergism between cannabinoid and COX pathways.107”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [107]
Cites
A method for measurement of analgesic activity on inflamed tissue.
Randall, L. O., & Selitto, J. J. (1957) · PubMed · Cited by 1,568 · see citing works
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741 · see citing works
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521 · see citing works
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491 · see citing works
Costa, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395 · see citing works
Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., & James, I. (2001) · Pain · doi:10.1016/s0304-3959(00)00474-7 · Cited by 379 · see citing works
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290 · see citing works
Antihyperalgesic effects of spinal cannabinoids
Richardson, J. D., Aanonsen, L., & Hargreaves, K. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01621-x · Cited by 275 · see citing works
Bridges, D., Ahmad, K., & Rice, A. S. C. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704110 · Cited by 221 · see citing works
Molina‐Holgado, F., Pinteaux, E., Moore, J. D., Molina‐Holgado, E., Guaza, C., Gibson, R. M., & Rothwell, N. J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-16-06470.2003 · Cited by 192 · see citing works
Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy
Rice, A. S. C., Farquhar-Smith, W. P., & Nagy, I. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0362 · Cited by 183 · see citing works
Hohmann, A. G. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00154-8 · Cited by 159 · see citing works
Scott, D. A., Wright, C. E., & Angus, J. A. (2004) · Pain · doi:10.1016/j.pain.2004.01.020 · Cited by 128 · see citing works
A role for endocannabinoids in indomethacin-induced spinal antinociception
Gühring, H., Hamza, M., Sergejeva, M., Ateş, M., Kotalla, C., Ledent, C. A., & Brune, K. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02485-8 · Cited by 121 · see citing works
Guindon, J., Léan, A. D., & Beaulieu, P. (2006) · Pain · doi:10.1016/j.pain.2005.12.007 · Cited by 105 · see citing works
Bingham, B., JONES, P. G., Uveges, A. J., Kotnis, S., Lu, P., Smith, V. A., Sun, S., Resnick, L., Chlenov, M., He, Y., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707303 · Cited by 93 · see citing works
Hillard, C. J., Muthian, S., & Kearn, C. S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01253-3 · Cited by 91 · see citing works
Costa, B., Colleoni, M., Conti, S., Trovato, A. E., Bianchi, M., Sotgiu, M. L., & Giagnoni, G. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705587 · Cited by 89 · see citing works
Ateş, M., Hamza, M., Seidel, K., Kotalla, C., Ledent, C. A., & Gühring, H. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02470.x · Cited by 77 · see citing works
The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats
Ulugöl, A., Karadağ, Ç. H., İpçi, Y., Tamer, M., & Dökmeci, İ. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.08.061 · Cited by 73 · see citing works
Doğrul, A., Gül, H., Yıldız, O., Bilgin, F., & Güzeldemir, M. E. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.060 · Cited by 61 · see citing works
Expression of cannabinoid CB1 receptors in models of diabetic neuropathy
Zhang, F., Hong, S., Stone, V., & Smith, P. J. W. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.128272 · Cited by 46 · see citing works
Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury
Hama, A., & Sagen, J. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.002 · Cited by 40 · see citing works
Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro
Coffey, R. G., Snella, E. M., Johnson, K. M., & Pross, S. H. (1996) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(97)85557-9 · Cited by 39 · see citing works
Cannabinoids and Neuropathic Pain
Goya, P., Jagerovic, N., Hernández‐Folgado, L., & Martín, M. (2003) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557033487818 · Cited by 32 · see citing works
The induction of diabetes in rats by intramuscular administration of streptozotocin
Nakhoda, A., & Wong, H. A. (1979) · Cellular and Molecular Life Sciences · doi:10.1007/bf01953269 · Cited by 29 · see citing works
Seidel, K., Hamza, M., Ateş, M., & Gühring, H. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01366-6 · Cited by 28 · see citing works
Bujalska‐Zadrożny, M., Tatarkiewicz, J., de Cordé, A., & Gumułka, S. W. (2007) · Pharmacology · doi:10.1159/000110787 · Cited by 28 · see citing works
Cannabinoids in anaesthesia and pain therapy
Azad, S. C., & Rammes, G. (2005) · Current Opinion in Anaesthesiology · doi:10.1097/01.aco.0000174959.05383.9c · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305 · see citing works
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301 · see citing works
Toth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174 · see citing works
Toth, C. C., Jedrzejewski, N. M., Ellis, C. L., & Frey, W. H. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-16 · Cited by 151 · see citing works
Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy
Barutta, F., Piscitelli, F., Pinach, S., Bruno, G., Gambino, R., Rastaldi, M. P., Salvidio, G., Marzo, V. D., Perin, P. C., & Gruden, G. (2011) · Diabetes · doi:10.2337/db10-1809 · Cited by 145 · see citing works
Exercise and Neuropathic Pain: A General Overview of Preclinical and Clinical Research
Leitzelar, B. N., & Koltyn, K. F. (2021) · Sports Medicine - Open · doi:10.1186/s40798-021-00307-9 · Cited by 84 · see citing works
Vincenzi, F., Targa, M., Corciulo, C., Tabrizi, M. A., Merighi, S., Gessi, S., Saponaro, G., Baraldi, P. G., Borea, P. A., & Varani, K. (2013) · Pain · doi:10.1016/j.pain.2013.02.007 · Cited by 63 · see citing works
Kumawat, V. S., & Kaur, G. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172628 · Cited by 57 · see citing works
González, C., Herradón, E., Abalo, R., Vera, G., Perez‐Nievas, B. G., Leza, J. C., Martin, M., & López‐Miranda, V. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1176 · Cited by 53 · see citing works
Hossain, M. Z., Ando, H., Unno, S., & Kitagawa, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041423 · Cited by 52 · see citing works
The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases
Argenziano, M., Tortora, C., Bellini, G., Paola, A. D., Punzo, F., & Rossi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235875 · Cited by 43 · see citing works
Cannabinoid system and cyclooxygenases inhibitors.
Păunescu, H., Oa, C., Coman, L., Ghiţă, I., Georgescu, Drăghia, F., & Fulga, I. (2011) · Europe PMC (PubMed Central) · Cited by 42 · see citing works
Vera, G., López‐Miranda, V., Herradón, E., Martı́n, M. I., & Abalo, R. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.05.008 · Cited by 41 · see citing works
Bujalska‐Zadrożny, M., de Cordé, A., & Pawlik, K. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.08.023 · Cited by 19 · see citing works
Li, Y., Sun, Y., Zhang, Z., Feng, X., Meng, H., Li, S., Zhu, Y., Chen, S., Wang, Y., Wang, J., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12172 · Cited by 17 · see citing works
Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice
Suo, M., Wang, P., & Zhang, M. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00229.2016 · Cited by 16 · see citing works
The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain
Bagher, A. M. (2021) · Journal of Microscopy and Ultrastructure · doi:10.4103/jmau.jmau_97_20 · Cited by 9 · see citing works
Vera, G., López‐Gómez, L., Girón, R., Martı́n, M. I., Nurgali, K., Abalo, R., & Uranga, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914430 · Cited by 6 · see citing works
Nocheva, H., Sabit, Z., & Grigorov, E. E. (2021) · Acta Medica Bulgarica · doi:10.2478/amb-2021-0005
Vera, G., Cabezos, P. A., Martín, M. I., & Abalo, R. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.02.008 · Cited by 68 · see citing works
- Authors
- Bujalska, M.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 82
- Issue
- 3
- Pages
- 193-200
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W2090462084
- Cited by
- 20
- References
- 29
- Citations by year
- 2023: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2017: 1 · 2016: 1 · 2014: 1 · 2013: 3 · 2012: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Keywords
- cannabinoid receptor agonists, diabetic neuropathy, hyperalgesia, WIN 55,212-2, AM1241, nitric oxide synthase inhibition, L-NNA, cyclooxygenase-1 inhibition, indomethacin, antihyperalgesia, synergistic analgesic effect
- MeSH terms
- Analgesics, Animals, Arachidonic Acids, Cannabinoids, Diabetes Mellitus, Experimental, Diabetic Neuropathies, Dose-Response Relationship, Drug, Drug Synergism, Hyperalgesia, Indomethacin, Male, Morpholines, Naphthalenes, Streptozocin, Cyclooxygenase Inhibitors, Rats, Wistar, Nitric Oxide Synthase, Nitroarginine, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, Benzoxazines, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
